June 5, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Kadmon Holdings Inc (NYSE:KDMN) shares over potential securities laws violations by Kadmon Holdings and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Kadmon Holdings Inc (NYSE:KDMN) concerning whether a series of statements by Kadmon Holdings Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

New York based Kadmon Holdings Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs

Kadmon Holdings Inc reported that its annual Total Revenue declined from $35.72 million in 2015 to $26.05 million in 2016 and that its Net Loss increased from $147.08 million to $208.75 million in 2016.

Shares of Kadmon Holdings Inc (NYSE:KDMN) declined from $10.23 per share in August 2016 to as low as $2.26 per share on May 31, 2017.